Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Fabrizio Di Costanzo
Observed names:
Di Costanzo, Fabrizio,
Fabrizio DI COSTANZO
Institutions:
Newcastle upon Tyne Hospitals NHS Foundation Trust,
Freeman Hospital,
Federico II University Hospital,
University of Naples Federico II,
University of Newcastle Australia,
Newcastle University
show all 6
Observed institutions:
Newcastle upon Tyne Hospitals NHS Foundation Trust,
Freeman Hospital,
Federico II University Hospital,
University of Naples Federico II,
University of Newcastle Australia,
Newcastle University
show all 6
ORCID:
0009-0001-2173-8245
Observed ORCID:
0009-0001-2173-8245
OpenAlex ID:
A5010268422
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
2024
·
Brigida Anna Maiorano
, Massimo Di Maio
, et al.
·
JAMA Network Open
·
66
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review
2022
·
Alberto Servetto
, Fabio Salomone
, et al.
·
Critical Reviews in Oncology/Hematology
·
27
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC
2022
·
Fabio Salomone
, Fabrizio Di Costanzo
, et al.
·
Lung Cancer
·
20
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes
2023
·
Alberto Servetto
, Massimo Di Maio
, et al.
·
BMC Medicine
·
10
PDF
Evaluating Treatment Efficacy in Metastatic Hormone-sensitive Prostate Cancer Patients with Visceral Disease: A Systematic Review and Network Meta-analysis
2025
·
Fabiano Flauto
, Giuseppe Neola
, et al.
·
European Urology Oncology
·
9
PDF
Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations
2026
·
Sara Elena Rebuzzi
, Aruni Ghose
, et al.
·
The Oncologist
·
4
Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness
2026
·
Fabrizio Di Costanzo
, Jack Williamson
, et al.
·
Molecular Cancer Therapeutics
·
4
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors
2023
·
Fabrizio Di Costanzo
, Fabiana Napolitano
, et al.
·
Cancers
·
4
PDF
Management of Advanced Germ Cell Tumours
2025
·
Fabrizio Di Costanzo
, Pasquale Rescigno
, et al.
·
Oncology Research and Treatment
·
3
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine
2026
·
Chiara Mercinelli
, Fabrizio Di Costanzo
, et al.
·
Expert Review of Anticancer Therapy
·
2
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis
2025
·
Fabrizio Di Costanzo
, Chiara Mercinelli
, et al.
·
The Oncologist
·
2
PDF
Real-world discontinuation and efficacy data of abiraterone acetate/prednisone (AAP) plus androgen deprivation therapy and radiotherapy in localized prostate cancer.
2025
·
Fabrizio Di Costanzo
, Xue Yan Jiang
, et al.
·
Journal of Clinical Oncology
·
2
Ribociclib in newly diagnosed hepatitis B infection: A case report
2023
·
Fabrizio Di Costanzo
, Simone Carrano
, et al.
·
Frontiers in Oncology
·
2
PDF
Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33—REGAL study
2026
·
Davide Bimbatti
, Cecilia Nasso
, et al.
·
Therapeutic Advances in Medical Oncology
·
1
Real-world comparative outcomes of first-line immune combinations (ICI–ICI vs ICI–TKI) in metastatic renal cell carcinoma with sarcomatoid features
2026
·
Sara Elena Rebuzzi
, Fabrizio Di Costanzo
, et al.
·
OncoImmunology
PDF
FGFR-altered urothelial carcinoma in the EV–pembrolizumab era: Rationale and emerging data for upfront triplet strategies
2026
·
Claudia Maria Ascione
, Raffaella Congi
, et al.
·
Critical Reviews in Oncology/Hematology
PDF
Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group
2026
·
Anna Amela Valsecchi
, Michele Maffezzoli
, et al.
·
Cancer and Metastasis Reviews
PDF
Gene expression analyses of immune tumor microenvironment in advanced renal cell carcinoma patients based on response to immunotherapy (Meet-URO 18 I-TME study)
2026
·
Sara Elena Rebuzzi
, Fabio Catalano
, et al.
·
Cancer Immunology Immunotherapy
Redefining the mCRPC frontline: lessons from PEACE-3 and BRCAaway in the post-ARPI era
2026
·
Giuseppe Luigi Banna
, Giuseppe Neola
, et al.
·
The Oncologist
Explainable machine learning to predict immunotherapy outcomes in metastatic renal cell carcinoma - Meet-URO 15-AI study
2026
·
Sara Elena Rebuzzi
, Vanja Miskovic
, et al.
·
npj Precision Oncology
PDF
Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study
2026
·
Pasquale RESCIGNO
, Tarek TAHA
, et al.
·
Minerva Urology and Nephrology
Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network
2026
·
Marilena Di Napoli
, Elisabetta Coppola
, et al.
·
Current Oncology
Treatment options in platinum-refractory male germ cell cancers: current standards and future directions
2026
·
Marco Oltrecolli
, Domiziana Alaimo
, et al.
·
Therapeutic Advances in Medical Oncology
Genomic analyses of bilateral testicular germ cell cancers (BITCOIN study) from the Italian Germ Cell Cancer Group (IGG).
2026
·
Sara Erika Bellomo
, Patrizia Giannatempo
, et al.
·
Journal of Clinical Oncology
PDF
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?—a narrative review
2025
·
Fabrizio Di Costanzo
, Iolanda Santa Parisi
, et al.
·
Chinese Clinical Oncology
Show more works
View as search
Works count:
31
Citation count:
156
H-index:
5
I10-index:
4
Year
Topic
Type